<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006003</url>
  </required_header>
  <id_info>
    <org_study_id>CE16256A</org_study_id>
    <nct_id>NCT03006003</nct_id>
  </id_info>
  <brief_title>Osteoporosis Treatment in Post-menopausal Women</brief_title>
  <official_title>The Assessment of Osteoporosis Treatment in Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted to assess the depressive symptoms and related markers in the
      postmenopausal female after anti-osteoporosis treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fracture is one of the important complications in female. Osteoporosis should be treated in
      postmenopausal female due to high risk of fracture. Recently, there have been many classes of
      medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis
      medication, has been reported to improved central nervous disorders. Therefore, this study is
      designed to assess the depressive symptoms and related markers in the postmenopausal female
      after anti-osteoporosis treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain-derived neurotrophic factor</measure>
    <time_frame>3 months</time_frame>
    <description>Serum brain-derived neurotrophic factor (BDNF) Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor</measure>
    <time_frame>1 year</time_frame>
    <description>Serum brain-derived neurotrophic factor (BDNF) Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular cell adhesion molecule-1</measure>
    <time_frame>3 months</time_frame>
    <description>Serum vascular cell adhesion molecule-1 (VCAM-1) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orexin-A</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Orexin-A levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body components</measure>
    <time_frame>3 months</time_frame>
    <description>Fat tissue ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zung self-rating depression scale</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire for depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-Item Geriatric Depression Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire for Cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mini Mental State Examination (MMSE)</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire for Cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Barthel index</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire for Cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living (IADL)</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire for Cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ankle-brachial index</measure>
    <time_frame>3 months</time_frame>
    <description>Peripheral artery disease assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Depressive Syndrome</condition>
  <arm_group>
    <arm_group_label>Raloxifene group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raloxifene treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To refuse anti-osteoporosis treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene</intervention_name>
    <description>Raloxifene tratment more than 4 weeks</description>
    <arm_group_label>Raloxifene group</arm_group_label>
    <other_name>Evista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronic acid 70mg with Colecalciferol 70mcg</description>
    <arm_group_label>Comparator group</arm_group_label>
    <other_name>FOSAMAX PLUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal female

          -  Osteoporosis

        Exclusion Criteria:

          -  Psychological disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>I-Te Lee, MD, PhD</last_name>
    <phone>+886-4-23741300</phone>
    <email>itlee@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>I-Te Lee, MD, PhD</last_name>
    <email>itlee@vghtc.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>December 26, 2016</last_update_submitted>
  <last_update_submitted_qc>December 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Raloxifene</keyword>
  <keyword>Central nervous disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

